An overview of patient monitoring strategies experts use to establish individualized followup with patients receiving therapy for OAB in the third-line setting.
Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.
Sponsored by AbbVie US Medical Affairs
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Multicomponent intervention boosts quality of life in overactive bladder patients
March 15th 2024A recent study reveals the efficacy of a cognitive behavior therapy program, showcasing significant improvements in health-related quality of life among women grappling with moderate to severe overactive bladder.
Read More